It is with great enthusiasm that we invite you to register for the second hybrid edition of CRSy, to be held at the Champalimaud Centre for the Unknown (CCU), in a stunning setting on the waterfront in Lisbon, Portugal, from October 19–21.

The overall goal of this event is to highlight examples from international funding entities that are either already piloting or considering implementing different models to allocate research funds, with a particular emphasis on the partial randomisation process, and highlight the perspective of researchers on this topic.

The session will end with a roundtable discussion featuring the views from researchers hosted by Portuguese institutions on whether partial randomisation is an appropriate alternative to the current peer review process.  

Early diagnosis aims to detect cancer in its early stages when it is potentially curable. This can apply not only to people who already have symptoms of a given cancer, but also to those who, not having any symptom, are subject to known risk factors that justify this approach.

Mr. P. started to be followed at the smoking cessation consultation of the Champalimaud Foundation in mid-2018. He had been a smoker for 33 years, and in 2018, he smoked around one pack of cigarettes a day. His first attempt to quit failed, but Mr. P. never quit the consultation and never gave up on quitting smoking. He finally achieved his goal in mid-2020 through a multidisciplinary approach (including psychology and psychiatry consultations) – and, to this day, has never smoked again.

To know more about this research:

Digest

Scientific Article

Funded by the MCSA & Citizens action - RAISE is built around a concept of co-creation that will blend Researchers at Schools (RAS) activities with European Researchers’ Nights (ERN) public events over the next two years.

What do the terms incidence and prevalence stand for? What do they measure? What are they used for?

Incidence and prevalence are two statistical measures of disease frequency that apply to any and every disease, although here we’ll just be concerned with cancer.

A portion of human gut – just removed from the abdomen of a colon cancer patient and opened in half so as to give access to its inner mucosa, – sits on the countertop. A technician starts to scan it with the tip of an optical fibre, hovering over the surface of the sample without touching it. On the scanned zones, streaks of various colours, as if the tissue is being “painted” by the laser beam coming out of the fibre optic. 

The Champalimaud Foundation and the IAEA are thus starting a partnership for the development of research, treatment and diagnosis of oncological diseases. The collaboration focuses on the areas of radiation oncology, diagnostic medical imaging, nuclear medicine and medical physics.

The BALANCE project, from the Cancer and Stem Cell Biology Lab at Champalimaud Research, will focus on medulloblastoma, one of the most common malignant brain tumours in children, and aims to “discover to what extent the developing brain is plastic and capable of compensating for the disturbances caused by the formation of a tumour, while maintaining its normal development and function”, as those responsible for the study say.